Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb - Research Grade |
---|---|
Source | CAS 214745-43-4 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Efalizumab,hu1124,ITGAL, CD11a,anti-ITGAL, CD11a |
Reference | PX-TA1040 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Efalizumab is a recombinant monoclonal antibody to Human CD11A. Under the trade name Raptiva, it is a drug that was previously used to treat autoimmune diseases and was originally used to treat psoriasis. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1 and inhibits lymphocyte activation and cell migration out of blood vessels into tissues. Efalizumab has been associated with fatal brain infections.
Efalizumab Biosimilar - Anti-ITGAL, CD11a mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.